Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women

Palomba, Stefano; Sammartino, A; Carlo, Costantino Di; Affinito, P.; Zullo, Fulvio; Nappi, Carmine

doi:10.1016/s0015-0282(01)01849-0

Cited by 101 publications

(53 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, no significant clinical benefits in terms of rise in haemoglobin or improved PBAC scores were demonstrated in studies with raloxifene [18] in normally cycling women but definite improved PBAC scores were shown in women with low estrogen [17].…”

Section: Discussionmentioning

confidence: 94%

“…This was possibly because the study group involved premenopausal subjects i.e. those with lower estrogen levels, where high doses of SERMS can inhibit leiomyoma growth but are ineffective in normally cycled women [17,18].…”

Section: Discussionmentioning

confidence: 99%

“…Clinical studies [11,17,18] have also shown that raloxifene significantly reduces mean uterine and leiomyoma size.…”

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

Evaluation of the SERM Ormeloxifene in the Treatment of Uterine Fibroid in the Reproductive Age Group

2016

J Syndr

View full text Add to dashboard Cite

Background: The search for the ideal drug for medical treatment of fibroids is on. SERMs appear to be novel agents for hormonal manipulations. Ormeloxifene with biweekly dosing and minimum side effects needs evaluation for the above. Method:The study was a prospective clinical observation undertaken to evaluate the efficacy of ormeloxifene in uterine fibroid in reproductive age group. Forty four (44) women aged 20-50 year age group who attended the outpatient gynaecology department, diagnosed with fibroid uterus; symptomatic or asymptomatic were recruited for the study. Ormeloxifene 60 mg was given orally twice a week for 6 months. Follow up was done at monthly interval and at the end of 6 months clinically and by USG. The primary outcome measures were fibroid size, uterine size and delta size. Secondary outcomes were measurement of menstrual blood loss using the PBAC score, hemoglobin concentration and endometrial thickness. Results:No significant changes were observed in the leiomyoma, uterine and delta size. 90.9% fibroids remained unchanged at the end of 6 months. The difference in mean hemoglobin concentration, PBAC scores and endometrial thickness were statistically significant (p<0.001). Hysterectomy was required in 5(11.36%) cases. Conclusion:Ormeloxifene does not reduce fibroid size but prevents further growth of the tumour and significantly reduces menstrual blood loss in standard doses with minimum side effects for a short period of time.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the SERM Ormeloxifene in the Treatment of Uterine Fibroid in the Reproductive Age Group

2016

J Syndr

View full text Add to dashboard Cite

show abstract

“…По имеющимся данным, лейомиоматозы характеризуются благоприят-ным прогнозом [1], однако при нерадикальном удалении рецидивы развиваются в 30% случаев [6], возможно при-менение антиэстрогенной терапии, чаще всего использу-ют тамоксифен и ралоксифен [7].…”

Section: ключевые слова: лейомиома матки внутрисосудистый лейомиоматunclassified

Intravascular leiomyomatosis

Andreeva¹,

Frank²,

Shikeeva³

et al. 2015

Arkh. patol.

View full text Add to dashboard Cite

Лейомиоматозы -группа гладкомышечных опухолей с неопределенным злокачественным потенциалом, объе-диняющая такие состояния, как диффузный лейомиома-тоз, агрессивный лейомиоматоз, интравенозный (внутри-сосудистый) лейомиоматоз, доброкачественная метаста-зирующая лейомиома, перитонеальный лейомиоматоз (паразитирующая лейомиома), диссеминирующий пери-тонеальный лейомиоматоз [1]. Ранее мы описывали кли-ническое наблюдение метастазирующей лейомиомы с кратким обзором литературы [2]. Настоящая статья по-священа интравенозному лейомиоматозу.Интравенозный лейомиоматоз (ИЛ) -редкое заболе-вание, характеризующееся формированием гладкомы-шечных опухолей с доброкачественными морфологиче-скими характеристиками в просвете и по ходу венозных каналов -истинных вен и венул матки, яичников, почек, Интравенозный лейомиоматоз -редкое заболевание из группы опухолей с неопределенным потенциалом злокачествен-ности. Приведено описание двух наблюдений интравенозного лейомиоматоза с подробной морфологической картиной и данными молекулярно-генетического исследования, кратким обзором литературы. В обоих случаях выявлены потери гете-розиготности микросателлитных повторов, расположенных на 10-й хромосоме, в районе 10q22.1, часто наблюдающиеся при лейомиосаркомах матки. Исследования морфологических и биологических характеристик лейомиоматоза важны для выяснения ключевых молекулярных механизмов развития данной нозологии и определения этиопатогенетических отно-шений между интравенозным лейомиоматозом и другими гладкомышечными новообразованиями матки. Ключевые слова: лейомиома матки, внутрисосудистый лейомиоматоз, лейомиосаркома, потеря гетерозиготности, микросателлитная нестабильность, миомэктомия, гистерэктомия.Intravenous leiomyomatosis is a rare disease from a group of tumors with the indefinite grading potential. The paper describes two cases of intravenous leiomyomatosis with its detailed morphological pattern, molecular genetic findings, and a brief literature review. Losses of heterozygosity of microsatellite repeats that were located on chromosome 10 in 10q22.1 and common in uterine leiomyosarcomas were found in both cases. Investigations of the morphological and biological characteristics of leimyomatosis are important to clarify the key molecular mechanisms underlying the development of this nosological entity and to determine etiopathogenetic relationships between intravenous leiomyomatosis and other uterine smooth muscle neoplasms.

show abstract

“…Raloxifene has been showed to enhance the shrinkage of uterine fibroids in postmenopausal women [33,34]. However, a recent report from Italy that addressed the effect of raloxifene on uterine leiomyoma showed that the leiomyoma size in premenopausal women who were administered daily 60-mg doses of raloxifene over a 2-year period exhibited no change in leiomyoma size [35].…”

Section: Serms and Treatment Of Uterine Fibroidsmentioning

confidence: 99%